Navigation Links
FDA Tells Patients to Stick With Diabetes Drug Linked to Cancer
Date:7/1/2009

There's no conclusive evidence that Lantus causes malignancy, agency says,,,,

WEDNESDAY, July 1 (HealthDay News) -- Despite recent studies suggesting that the injected diabetes drug Lantus (insulin glargine) might boost cancer risk, the U.S. Food and Drug Administration on Wednesday urged patients who are on the medication to continue using it.

Three of four studies published last Friday in Diabetologia showed a potential link between Lantus -- an insulin analogue made by French drug company Sanofi-aventis -- and increased risks for various tumor types.

But, "the duration of patient follow-up in all four studies was shorter than what is generally considered necessary to evaluate for cancer risk from drug exposure," the FDA said in its first comment on the issue. "Further, inconsistencies in findings within and across individual studies raise concerns as to whether an association between the use of insulin glargine and cancer truly exists."

The agency also believes that differences in the various types of patients selected for each study may have swayed the results.

"Based on the currently available data, the FDA recommends that patients should not stop taking their insulin therapy without consulting a physician, since uncontrolled blood sugar levels can have both immediate and long-term serious adverse effects," the agency wrote.

A statement released Friday by the American Diabetes Association echoed the FDA's position. "For patients using glargine and considering switching to another form of insulin, the data in these studies make it unclear as to whether any one type of insulin increases the risk of cancer more than other types of insulin," the ADA said. "Patients concerned about these studies or their insulin regimen should talk to their doctor and should not stop taking their insulin on the basis of the findings reported here."

Lantus is an "analogue," or artificial version, of insulin and is used by both type 1 and type 2 diabetics to help control blood sugar over an extended period of time. It is given by injection once daily.

The FDA says it is "currently reviewing many sources of safety data for Lantus," including completed and ongoing observational and clinical trials, and may ask Sanofi to conduct further trials should they be deemed necessary.

According to the Wall Street Journal, a spokesman for Sanofi said that the company is working with the FDA on this issue and continues to stand behind the drug's safety.

In the meantime, the FDA says it "encourages both health care professionals and patients to report side effects from the use of insulin glargine to the FDA's MedWatch Adverse Event Reporting Program."

More information

Find out more about diabetes at the American Diabetes Association.



-- E.J. Mundell



SOURCES: July 1, 2009, statement, U.S. Food and Drug Administration; June 26, 2009, statement, American Diabetes Association; Wall Street Journal


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Drummer Eddie Cleland Resumes Life After Brain Surgery and Tells About it at Conference
2. Every Picture Tells A Story, Particularly for Those With Epilepsy
3. Patient Command Tells Sec. Sebelius That Existing Technology Can Make Electronic Health Records Interoperable
4. Easy-to-Use Wristband Tells You When to Apply Sunscreen - and When to Hit the Shade
5. Health Workforce Reform Fundamental to Successful Health Reform, AAHC tells Obama Administration
6. What Is It Like to Survive a Plane Crash? A Survivor of One of the Worst Small Plane Crashes Tells Her Story
7. Especially Among Children, Prevention is Key to Halting Obesity Epidemic, President of American Dietetic Association Tells Congressional Subcommittee
8. Coast IRB Tells Congressional Committee Sting Operation Was Illegal, Unnecessarily Harmful
9. Young Tells Congress Survival of Postal Service Could Depend on Passage of Relief Legislation
10. Health Reform Must Include Health Workforce, AAHC President Tells Congress
11. Is one diet as good as another? U of I study says no and tells you why
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Tells Patients to Stick With Diabetes Drug Linked to Cancer
(Date:12/6/2016)... ... December 06, 2016 , ... Healthcare ... federal healthcare regulations at the 7th annual Health IT Leadership Summit, to be ... acting administrator for the Centers for Medicare & Medicaid Services (CMS), will be ...
(Date:12/6/2016)... PA (PRWEB) , ... December 06, 2016 , ... ... identification and characterization laboratories, is now offering HIAC particle counting and sizing services ... immediately. , Gateway Analytical instituted the new service as a response to the ...
(Date:12/6/2016)... ... 06, 2016 , ... 'Tis the season for family, festivity, food and fun! ... the season when eating healthy, staying active, and taking medication and doing daily foot ... do. , "Shopping trips, parties and family gatherings can take their toll on ...
(Date:12/6/2016)... ... 2016 , ... The OSHA Training Center at Chabot-Las ... headquartered in Northern California, has announced the addition of a Public Sector Safety ... to public sector employees. , “The primary goal of the Public Sector Safety ...
(Date:12/5/2016)... TX (PRWEB) , ... December 05, 2016 , ... ... for Facial Plastic Surgery, is excited to announce the arrival of the newest ... fractional laser, with the ability to use tunable non-ablative and ablative wavelengths for ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... 2016 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: ... R&D program in the use of cannabinoids for ... In June, 2015 InMed initiated its COPD program ... targets and potential active compounds that can be ... in vitro assays using human lung fibroblasts (HFL-1 ...
(Date:12/5/2016)...  Balloon catheter is an innovative medical device that ... femoral artery in the leg or sometimes into the ... vessels. These products are generally used to prevent blood ... lipid substances in the blood vessel. In terms of ... expand at a CAGR of 3.8% during the forecast ...
(Date:12/5/2016)... , Dec. 5, 2016 Spain Glaucoma ... GlobalData,s new report, "Spain Glaucoma Surgery Devices Market Outlook ... Glaucoma Surgery Devices market. The report provides value, in ... prices (USD) within market segements - Canaloplasty Micro Catheters ... company shares and distribution shares data for each of ...
Breaking Medicine Technology: